View of Prospective Evaluation of Atrial Fibrillation Risk in Type 2 Diabetes Comparing SGLT-2 Inhibitors and DPP-4 Inhibitors

Return to Article Details Prospective Evaluation of Atrial Fibrillation Risk in Type 2 Diabetes Comparing SGLT-2 Inhibitors and DPP-4 Inhibitors Download Download PDF